StreetInsider.com News Articles

Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud

Tue, 21 Jul 2026 07:53:41 -0400

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom.

Novo Nordisk Inc. filed a lawsuit in the U.S. District Court for the District of New Jersey against Eli Lilly and Company and Lilly USA, LLC, alleging multiple violations of federal and state false advertising and unfair competition laws under the Lanham Act.

The lawsuit takes aim at Lilly’s aggressive direct-to-consumer (DTC) advertising campaigns for its blockbuster tirzepatide drugs, Zepbound and Mounjaro. Novo Nordisk claims the ads are false and misleading because they

Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud

Tue, 21 Jul 2026 07:53:41 -0400

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom.

Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud

Tue, 21 Jul 2026 07:53:41 -0400

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom.

Novo Nordisk sues Eli Lilly in high-stakes GLP-1 advertising feud

Tue, 21 Jul 2026 07:53:41 -0400

Investing.com -- The clash between pharma titans Novo Nordisk and Eli Lilly just escalated from the pharmacy counter to the courtroom.

Novo Nordisk sues Eli Lilly over weight-loss drug ads

Tue, 21 Jul 2026 07:36:27 -0400

Investing.com -- Novo Nordisk filed a lawsuit on Tuesday against Eli Lilly in U.S. District Court in New Jersey, claiming the American pharmaceutical company engaged in false advertising by stating its weight-loss medications perform better than Novo's products.

The Danish drugmaker said the lawsuit alleges Lilly violated federal and state false advertising and unfair competition laws, including the Lanham Act, through nationwide advertising campaigns for obesity drug Zepbound and diabetes treatment Mounjaro.

According to Novo, Lilly compared the highest approved doses of its medications with lower doses of Novo's Wegovy and Ozempic while leaving out newer, higher-dose versions that Novo says produce

Novo Nordisk sues Eli Lilly over weight-loss drug ads

Tue, 21 Jul 2026 07:36:27 -0400

According to Novo, Lilly compared the highest approved doses of its medications with lower doses of Novo's Wegovy and Ozempic while leaving out newer, higher-dose versions that Novo says produce

Form 6-K NOVO NORDISK A S For: Jul 20

Tue, 21 Jul 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260721/26791618.html

Form 6-K NOVO NORDISK A S For: Jul 20

Tue, 21 Jul 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260721/26791618.html

Form 6-K NOVO NORDISK A S For: Jul 20

Tue, 21 Jul 2026 06:04:00 -0400

si-local-file:///var/storage/secattach/20260721/26791618.html

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK330 at Citi

Mon, 20 Jul 2026 05:07:42 -0400

Citi analyst Graham Parry raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK330.00 (from DKK290.00) while maintaining a Neutral rating.

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK330 at Citi

Mon, 20 Jul 2026 05:07:42 -0400

Citi analyst Graham Parry raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK330.00 (from DKK290.00) while maintaining a Neutral rating.

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK330 at Citi

Mon, 20 Jul 2026 05:07:42 -0400

Citi analyst Graham Parry raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK330.00 (from DKK290.00) while maintaining a Neutral rating.

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK330 at Citi

Mon, 20 Jul 2026 05:07:42 -0400

Citi analyst Graham Parry raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK330.00 (from DKK290.00) while maintaining a Neutral rating.

Novo Nordisk wins EU approval for Wegovy pill and new injection

Wed, 15 Jul 2026 11:53:57 -0400

Novo Nordisk has received European Commission marketing authorisation for Wegovy (once-daily oral semaglutide 25 mg) as a treatment for adults with obesity or overweight, the company announced on July 15, 2026. The approval marks the drug's fifth regulatory clearance, following earlier approvals in the US, UK, UAE, and Bahrain.

The pill is approved for adults with a BMI of 30 kg/m² or above, or those with a BMI of 27 kg/m² or above with at least one weight-related comorbidity, when used alongside a reduced-calorie diet and increased physical activity.

The approval is based on the OASIS clinical trial programme, including the OASIS

Novo Nordisk wins EU approval for Wegovy pill and new injection

Wed, 15 Jul 2026 11:53:57 -0400

The approval is based on the OASIS clinical trial programme, including the OASIS

Form 6-K NOVO NORDISK A S For: Jul 13

Mon, 13 Jul 2026 09:24:00 -0400

si-local-file:///var/storage/secattach/20260713/26760801.html

Form 6-K NOVO NORDISK A S For: Jul 13

Mon, 13 Jul 2026 09:24:00 -0400

si-local-file:///var/storage/secattach/20260713/26760801.html

Form 6-K NOVO NORDISK A S For: Jul 13

Mon, 13 Jul 2026 09:24:00 -0400

si-local-file:///var/storage/secattach/20260713/26760801.html

Form 6-K NOVO NORDISK A S For: Jul 06

Mon, 06 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260706/26732554.html

Form 6-K NOVO NORDISK A S For: Jul 06

Mon, 06 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260706/26732554.html

Form 6-K NOVO NORDISK A S For: Jul 06

Mon, 06 Jul 2026 07:00:00 -0400

si-local-file:///var/storage/secattach/20260706/26732554.html

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK300 at HSBC

Mon, 06 Jul 2026 01:32:44 -0400

HSBC analyst Rajesh Kumar raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK300.00 (from DKK280.00) while maintaining a Hold rating.

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK300 at HSBC

Mon, 06 Jul 2026 01:32:44 -0400

HSBC analyst Rajesh Kumar raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK300.00 (from DKK280.00) while maintaining a Hold rating.

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK300 at HSBC

Mon, 06 Jul 2026 01:32:44 -0400

HSBC analyst Rajesh Kumar raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK300.00 (from DKK280.00) while maintaining a Hold rating.

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK300 at HSBC

Mon, 06 Jul 2026 01:32:44 -0400

HSBC analyst Rajesh Kumar raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK300.00 (from DKK280.00) while maintaining a Hold rating.